Market news: Novo Nordisk's ZILTIVEKIMAB did not show a lower risk of syphilis than placebo.

Zhitongcaijing · 1d ago
Market news: Novo Nordisk's ZILTIVEKIMAB did not show a lower risk of syphilis than placebo.